Universität zu Köln

Rehberg, Mirko, Winzenrieth, Renaud, Hoyer-Kuhn, Heike, Duran, Ibrahim ORCID: 0000-0003-4044-8822, Schoenau, Eckhard and Semler, Oliver (2019). TBS as a Tool to Differentiate the Impact of Antiresorptives on Cortical and Trabecular Bone in Children With Osteogenesis Imperfecta. J. Clin. Densitom., 22 (2). S. 229 - 236. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1559-0747

Full text not available from this repository.

Abstract

Introduction/Background: Osteogenesis imperfecta is a hereditary connective tissue disorder, resulting in low bone mass and high bone fragility. Dual-energy X-ray absorptiometry (DXA) and in adulthood also the trabecular bone score (TBS) are well established to assess bone health and fracture risk. The purpose of this investigation was to assess the usefulness of TBS in respect to different treatment regimes in children with osteogenesis imperfecta. Changes of areal bone mineral density (aBMD) and TBS using DXA scans of children treated with antiresorptive therapies were evaluated. Methodology: DXA scans (aBMD, TBS) of 8 children with CM were evaluated. The scans were taken during a 1 yr period of treatment with bisphosphonates and during 1 yr pilot trial using denosumab. Changes of aBMD and TBS during both treatment regimens were compared. Results: During bisphosphonate treatment aBMD increased about 6.2%, while TBS increased about 2.1%. The difference between aBMD and TBS before and after bisphosphonate treatment was not significant (p = 0.25). During denosumab treatment aBMD increased around 25.1%, while TBS increased 6.7%. The change of aBMD was significant (p = 0.007), as was the difference between aBMD and TBS (p < 0.001). Conclusions: Denosumab had a significant effect on both aBMD and TBS but was significantly more pronounced in aBMD. These results suggest a stronger effect of denosumab on cortical bone and the growth plate in comparison to bisphosphonates. Beside the lack of paediatric reference data and the small sample size, the results suggest TBS to be a useful tool for monitoring skeletal changes during development, growth, and antiresorptive therapy in children with OI.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Rehberg, Mirko UNSPECIFIED UNSPECIFIED UNSPECIFIED Winzenrieth, Renaud UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoyer-Kuhn, Heike UNSPECIFIED UNSPECIFIED UNSPECIFIED Duran, Ibrahim UNSPECIFIED orcid.org/0000-0003-4044-8822 UNSPECIFIED Schoenau, Eckhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Semler, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-151678
DOI:	10.1016/j.jocd.2018.09.001
Journal or Publication Title:	J. Clin. Densitom.
Volume:	22
Number:	2
Page Range:	S. 229 - 236
Date:	2019
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1559-0747
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTRAVENOUS PAMIDRONATE; SCORE TBS; DENSITY; MICROARCHITECTURE; NERIDRONATE; ADOLESCENTS; CHILDHOOD; FRACTURES; DENOSUMAB; STRENGTH Multiple languages Endocrinology & Metabolism Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15167